Therapeutic Options for Neuroendocrine Tumors | Zendy

Reto M. Kaderli | Zendy; Marko Spanjol | Zendy; Attila Kollár | Zendy; Lukas Bütikofer | Zendy; Viktoria Gloy | Zendy; Rebecca A. Dumont | Zendy; Christian Seiler | Zendy; Emanuel Christ | Zendy; Piotr Radojewski | Zendy; Matthias Briel | Zendy; Martin A. Walter | Zendy

AI Assistant Blog Pricing

Open Access

Therapeutic Options for Neuroendocrine Tumors

Author(s) -

Reto M. Kaderli,

Marko Spanjol,

Attila Kollár,

Lukas Bütikofer,

Viktoria Gloy,

Rebecca A. Dumont,

Christian Seiler,

Emanuel Christ,

Piotr Radojewski,

Matthias Briel,

Martin A. Walter

Publication year - 2019

Publication title -

jama oncology

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2018.6720

Subject(s) - medicine , randomized controlled trial , meta analysis , medline , adverse effect , neuroendocrine tumors , clinical trial , data extraction , guideline , systematic review , oncology , intensive care medicine , pathology , law , political science

Multiple therapies are currently available for patients with neuroendocrine tumors (NETs), yet many therapies have not been compared head-to-head within randomized clinical trials (RCTs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog